Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Y14
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Y14 is a novel extended-release peptide YY analogue developed for the treatment of obesity. It is a human PYY analogue based on human PYY1-36, designed to act as a selective agonist of the human Neuropeptide Y receptor Y2. The drug utilizes a zinc-based extended-release formulation to allow for weekly or fortnightly administration. Clinical trials have shown Y14 to be well-tolerated, leading to significant reductions in body weight and food intake in overweight/obese volunteers. It was developed by Zihipp, Ltd. with funding from the UK Medical Research Council.
- Other names
- peptide YY analoguePYY analoguePYY(3-36) analogue
02
Targets
NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on Y14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Y14.